| Company | Date | Position | Consensus β | Price Target β | 1-Yr Return | vs S&P 500 β |
|---|---|---|---|---|---|---|
|
AXGN
AxoGen
|
Oct 29, 2026 | BUY |
Strong Buy
-17.4% avg upside
21 analysts
|
$56.00
13.52% Upside
|
+11.8% | Β· |
|
BSX
Boston Scientific
|
Oct 29, 2026 | BUY |
Strong Buy
+43.0% avg upside
38 analysts
|
$50.00
19.15% Upside
|
+3.9% | Β· |
|
ISRG
Intuitive Surgical
|
Oct 21, 2026 | BUY |
Strong Buy
+12.0% avg upside
37 analysts
|
$503.00
16.34% Upside
|
+3.6% | Β· |
|
EW
Edwards Lifesciences
|
Oct 15, 2026 | BUY |
Strong Buy
+10.0% avg upside
35 analysts
|
$101.00
9.67% Upside
|
+21.6% | Β· |
|
PODD
Insulet
|
Oct 12, 2026 | HOLD |
Strong Buy
+40.0% avg upside
32 analysts
|
$143.00
4.41% Downside
|
+9.1% | Β· |
|
PRCT
PROCEPT BioRobotics
|
Oct 12, 2026 | HOLD |
Buy
+59.9% avg upside
18 analysts
|
$20.00
4.25% Upside
|
+21.6% | Β· |
|
ZBH
Zimmer Biomet Holdings
|
Oct 12, 2026 | HOLD |
Buy
+20.5% avg upside
39 analysts
|
$97.00
2.57% Upside
|
+11.9% | Β· |
|
SYK
Stryker
|
Oct 12, 2026 | BUY |
Strong Buy
+18.5% avg upside
38 analysts
|
$353.00
20.96% Upside
|
+12.8% | Β· |
|
BBNX
Beta Bionics, Inc.
|
Sep 17, 2026 | BUY |
Strong Buy
+45.7% avg upside
17 analysts
|
$27.00
61.19% Upside
|
-23.4% | Β· |
|
MDT
Medtronic
|
Jul 10, 2026 | BUY |
Buy
+4.4% avg upside
38 analysts
|
β | +23.6% | Β· |
|
PEN
Penumbra
|
Jan 15, 2026 | HOLD |
Buy
+3.6% avg upside
23 analysts
|
$374.00
17.25% Upside
|
-8.4% | Β· |
|
ABT
Abbott Laboratories
|
Oct 16, 2025 | HOLD |
Strong Buy
+8.5% avg upside
36 analysts
|
$136.00
28.04% Upside
|
-15.8% | Β· |
|
TNDM
Tandem Diabetes Care
|
Oct 14, 2025 | BUY |
Buy
+64.3% avg upside
29 analysts
|
$29.00
51.84% Upside
|
+11.3% | Β· |
|
CRC
California Resources Corp
|
Oct 14, 2025 | BUY |
Strong Buy
+33.0% avg upside
21 analysts
|
β | +12.0% | Β· |
|
INSP
Inspire Medical Systems
|
Oct 14, 2025 | HOLD |
Buy
+30.4% avg upside
21 analysts
|
$96.00
41.02% Upside
|
-13.7% | Β· |
|
DXCM
Dexcom
|
Oct 14, 2025 | BUY |
Strong Buy
+31.4% avg upside
33 analysts
|
$84.00
2.13% Upside
|
+26.1% | Β· |
|
VCEL
Vericel
|
Oct 14, 2025 | BUY |
Strong Buy
+16.3% avg upside
16 analysts
|
$48.00
19.30% Upside
|
+16.2% | Β· |
|
NPCE
NeuroPace
|
Aug 13, 2025 | BUY |
Strong Buy
+46.9% avg upside
14 analysts
|
$18.00
46.31% Upside
|
+55.7% | Β· |
|
JNJ
Johnson & Johnson
|
Apr 05, 2024 | BUY |
Strong Buy
-9.1% avg upside
40 analysts
|
β | +3.8% | Β· |
|
LLY
Eli Lilly & Co
|
Oct 16, 2023 | BUY |
Strong Buy
-16.7% avg upside
50 analysts
|
β | +49.6% | Β· |
|
PLRX
Pliant Therapeutics
|
Sep 26, 2023 | BUY |
Buy
+2494.5% avg upside
21 analysts
|
$46.00
5255.78% Upside
|
-33.0% | Β· |
|
KYMR
Kymera Therapeutics
|
May 04, 2023 | HOLD |
Strong Buy
-9.6% avg upside
39 analysts
|
$31.00
75.61% Downside
|
+42.5% | Β· |
|
VRDN
Viridian Therapeutics
|
Aug 15, 2022 | BUY |
Strong Buy
+42.6% avg upside
32 analysts
|
$40.00
62.19% Upside
|
-11.1% | Β· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.